An update on the pathophysiology of sepsis

Area of Science:

• Critical care medicine
• Immunology
• Pathophysiology

Background:

• Sepsis remains a leading cause of mortality in critically ill patients, with a significant death rate despite current interventions.
• Previous therapeutic strategies primarily focused on anti-inflammatory approaches, largely failing to demonstrate efficacy in human trials.
• The complexity of sepsis, characterized by a biphasic immune response including inflammation and subsequent immune suppression, challenges single-target therapies.

Purpose of the Study:

• To elucidate the complex pathophysiology of sepsis beyond a simple inflammatory response.
• To highlight the limitations of solely targeting pro-inflammatory mechanisms in sepsis treatment.
• To emphasize the potential of novel therapeutic avenues by considering the biphasic nature of sepsis and its mediators.

Main Methods:

• Review of existing literature on sepsis pathophysiology and therapeutic interventions.
• Analysis of the role of cytokines and the coagulation cascade in sepsis.
• Evaluation of the reasons for the failure of anti-inflammatory strategies in human sepsis trials.

Main Results:

• Sepsis involves a dynamic, biphasic immune response, not just uncontrolled inflammation.
• A subsequent period of immune suppression follows the initial pro-inflammatory phase.
• Patients may experience repeated oscillations between pro- and anti-inflammatory states.

Conclusions:

• A single therapeutic agent is unlikely to be effective against sepsis due to its complex, biphasic nature.
• Modulating cytokines and targeting the coagulation cascade represent promising therapeutic strategies for sepsis.
• A comprehensive understanding of sepsis pathophysiology is essential for developing successful treatments.